JP2015531396A5 - - Google Patents

Download PDF

Info

Publication number
JP2015531396A5
JP2015531396A5 JP2015535741A JP2015535741A JP2015531396A5 JP 2015531396 A5 JP2015531396 A5 JP 2015531396A5 JP 2015535741 A JP2015535741 A JP 2015535741A JP 2015535741 A JP2015535741 A JP 2015535741A JP 2015531396 A5 JP2015531396 A5 JP 2015531396A5
Authority
JP
Japan
Prior art keywords
monoclonal antibody
antibody
subject
mabp1
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015535741A
Other languages
English (en)
Other versions
JP6750941B2 (ja
JP2015531396A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/062899 external-priority patent/WO2014055541A1/en
Publication of JP2015531396A publication Critical patent/JP2015531396A/ja
Publication of JP2015531396A5 publication Critical patent/JP2015531396A5/ja
Application granted granted Critical
Publication of JP6750941B2 publication Critical patent/JP6750941B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (7)

  1. ヒト被験者の不安を軽減するための医薬品の製造における、医薬的に許容可能なキャリアと、前記被験者の不安を軽減するのに有効な量の、IL−1αと選択的に結合する剤とを含む医薬組成物の使用
  2. 請求項1に記載の使用において、前記剤は、抗−IL−1α抗体であることを特徴とする使用
  3. 請求項2に記載の使用において、前記抗−IL−1α抗体は、モノクローナル抗体であることを特徴とする使用
  4. 請求項3に記載の使用において、前記モノクローナル抗体は、IgG1であることを特徴とする使用
  5. 請求項3に記載の使用において、前記モノクローナル抗体は、MABp1の相補性決定領域を含むことを特徴とする使用
  6. 請求項3に記載の使用において、前記モノクローナル抗体は、MABp1であることを特徴とする使用
  7. 請求項1に記載の使用において、前記被験者は、ざ瘡があることを特徴とする使用
JP2015535741A 2012-10-04 2013-10-01 精神障害の治療 Active JP6750941B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261709741P 2012-10-04 2012-10-04
US61/709,741 2012-10-04
PCT/US2013/062899 WO2014055541A1 (en) 2012-10-04 2013-10-01 Treatment of psychiatric conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020090717A Division JP2020143133A (ja) 2012-10-04 2020-05-25 精神障害の治療

Publications (3)

Publication Number Publication Date
JP2015531396A JP2015531396A (ja) 2015-11-02
JP2015531396A5 true JP2015531396A5 (ja) 2016-11-17
JP6750941B2 JP6750941B2 (ja) 2020-09-02

Family

ID=50435375

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015535741A Active JP6750941B2 (ja) 2012-10-04 2013-10-01 精神障害の治療
JP2020090717A Pending JP2020143133A (ja) 2012-10-04 2020-05-25 精神障害の治療
JP2022144756A Withdrawn JP2022177132A (ja) 2012-10-04 2022-09-12 精神障害の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020090717A Pending JP2020143133A (ja) 2012-10-04 2020-05-25 精神障害の治療
JP2022144756A Withdrawn JP2022177132A (ja) 2012-10-04 2022-09-12 精神障害の治療

Country Status (7)

Country Link
EP (1) EP2903643A4 (ja)
JP (3) JP6750941B2 (ja)
KR (1) KR20150064091A (ja)
CN (1) CN104684581A (ja)
AU (1) AU2013327498B2 (ja)
CA (1) CA2886757C (ja)
WO (1) WO2014055541A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011268229B2 (en) 2010-06-18 2015-04-16 Xbiotech Inc. Arthritis treatment
NZ607472A (en) 2010-08-23 2014-09-26 Xbiotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN108404127A (zh) 2011-09-23 2018-08-17 埃克斯生物科技公司 恶病质治疗
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
MX2019009798A (es) * 2017-02-16 2020-01-30 Xbiotech Inc Tratamiento de la hidradenitis supurativa.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405021D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
US5455234A (en) * 1994-03-16 1995-10-03 Ahluwalia; Gurpreet S. Inhibition of hair growth
JP2002226457A (ja) * 2001-02-02 2002-08-14 Ajinomoto Co Inc 新規シスチン誘導体及び炎症因子活性化抑制剤
RU2498998C2 (ru) * 2008-05-30 2013-11-20 ИксБиотеч, Инк. АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ
TW201031421A (en) * 2009-01-29 2010-09-01 Abbott Lab IL-1 binding proteins
AU2012236106B2 (en) * 2011-04-01 2016-12-08 Janssen Biotech, Inc. Treatment for dermatological pathologies
US9724409B2 (en) * 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease

Similar Documents

Publication Publication Date Title
JP2015531396A5 (ja)
JP2014509662A5 (ja)
IL240179A0 (en) Use of a chimeric human monoclonal antibody that binds to il-5r in the production of a drug to reduce the number of basophils in a person's blood
NZ630363A (en) Anti-kit antibodies and uses thereof
IL240731B (en) An antibody that binds the p19 subunit of il-23, its production process, a pharmaceutical preparation containing it and its use in cancer treatment
MY184154A (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
PH12014501685A1 (en) Humanized antibodies that recognize alpha-synuclein
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
AR059922A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
IL212633A (en) A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
JP2014111603A5 (ja)
MX370234B (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
BR112013002167A2 (pt) anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
BR112012013093A2 (pt) ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
JP2010222367A5 (ja)
HK1213782A1 (zh) 在診斷和治療類風濕性關節炎中使用的包含抗- 單克隆抗體的藥物組合物
JP2012136529A5 (ja)
WO2018111670A3 (en) Antibodies to human alpha-synuclein
JP2015524816A5 (ja)
JP2014526559A5 (ja)
JP2015531397A5 (ja)
WO2014185908A3 (en) Hybridoma clones, monoclonal antibodies, and methods of use
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán